Latest filing published 02 Sept 2026 for AN2 Therapeutics, Inc., €9,989.
Filing timeline
BuySaleInsider track record
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
No signal scores available.
Margaret M. FitzPatrick: trading record in brief
Margaret M. FitzPatrick discloses dealings in AN2 Therapeutics, Inc. to SEC (Form 4). Between 28 May 2025 and 1 September 2026, the trades on record add up to 2 filings.
Purchases make up the whole of the open-market record (2 purchases, €19k). Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Since January 2026: 1 purchase and no sales on the market.
On 2 September 2026 came the latest disclosure, an open-market purchase for €9,989 in AN2 Therapeutics, Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Margaret M. FitzPatrick
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 2,098 shares@ US$5.53Common StockSEC:0001193125-26-380595:0Canonical exit: 30 Nov 2026 (T+90)
- 8,610 shares@ US$1.1769100.0% of flowCommon StockSEC:0000950170-25-078982:0Canonical exit: 26 Aug 2025 (T+90)
2 of 2 declarations
